graft

(redirected from Bypass Graft)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms.

graft,

in surgery: see transplantation, medicaltransplantation, medical,
surgical procedure by which a tissue or organ is removed and replaced by a corresponding part, usually from another part of the body or from another individual.
..... Click the link for more information.
.

graft

[graft]
(biology)
To unite to form a graft.
A piece of tissue transplanted from one individual to another or to a different place on the same individual.
An individual resulting from the grafting of parts.
(botany)
To unite a scion to an understock in such manner that the two grow together and continue development as a single plant without change in scion or stock.

graft

To join a scion, shoot, or bud to the stock of another similar plant.

graft

1. Horticulture
a. a piece of plant tissue (the scion), normally a stem, that is made to unite with an established plant (the stock), which supports and nourishes it
b. the plant resulting from the union of scion and stock
c. the point of union between the scion and the stock
2. Surgery a piece of tissue or an organ transplanted from a donor or from the patient's own body to an area of the body in need of the tissue
References in periodicals archive ?
There are 2 types of bypass graft aneurysms: true aneurysms and pseudo aneurysms.
As a result of the completed transaction, Nervation will have the exclusive rights to the Vasculink Vascular Access Graft and the Myolink Arterial Bypass Graft and CardioTech will retain the exclusive rights to the CardioPass Coronary Artery ByPass Graft.
Dutcher continued, "We asked the FDA for broad labeling claims including AngioJet System use in native coronary arteries and saphenous vein bypass grafts, in patients experiencing angina (chest pain) and heart attack, and in patients contraindicated for drug lysis therapy -- we were given all the usage indications we requested.
Coronary artery bypass graft (CABG) surgery is performed about 350,000 times annually in the United States, making it one of the most commonly performed major operations.
Its three products -- the AngioJet(R) Rapid Thrombectomy System, the Perma-Flow(R) Coronary Bypass Graft and the Perma-Seal(R) Dialysis Access Graft -- are highly differentiated, next-generation medical devices that have the potential to become preferred treatment options.
The Perma-Flow Coronary Bypass Graft is beginning to be marketed in the nations of the European Union by the Company's worldwide marketing partner, Baxter HealthCare Corporation, under the CE Mark the Company recently received.
The CE Mark allows the AngioJet System to be sold specifically for use in removing blood clots from coronary arteries and bypass grafts throughout the European Union, one of the largest markets for medical devices in the world.
The company's initial therapeutic focus for Anginera is as an adjunct therapy in patients undergoing coronary artery bypass graft (CABG) surgery.
Douglas Murphy, became the first surgeon ever to implant the Perma-Flow Coronary Bypass Graft onto a beating heart.
The product's unique combination of features is crucial for improving both the immediate and long-term success of hemodialysis access, bypass graft and angioplasty procedures.
Its three key products -- the AngioJet(TM) Rapid Thrombectomy System, the Perma-Flow(R) Coronary Bypass Graft and the Perma-Seal(R) Dialysis Access Graft -- are in human clinical trials in the United States and in early stage sales in Europe, Japan and Canada.
Possis Medical's three key products, the AngioJet Peripheral Thrombectomy System, Perma- Flow Coronary Bypass Graft and Perma-Seal Dialysis Access Graft are in human clinical trials in the United States and early stage sales in Europe, Japan and Canada.